nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.05.2010 | Original Article

Effects of hormone replacement therapy on glucose and lipid profiles and on cardiovascular risk parameters in postmenopausal women

verfasst von: Banu Bingol, Ziya Gunenc, Murat Yilmaz, Aydan Biri, Bülent Tiras, Haldun Güner

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The aim of this study was to evaluate the effects of hormone replacement therapy (HRT) on carbohydrate and lipid metabolisms and cardiovascular risk parameters in healthy postmenopausal women.

Methods

Forty women receiving and 38 women not receiving HRT were included and baseline and sixth month blood pressure, weight, body mass index, waist/hip ratio, blood lipid profile, inflammatory markers (homocysteine, C-reactive protein (CRP) and fibrinogen), hemoglobin A1c (HbA1c) and insulin, and oral glucose tolerance test (OGTT) results were evaluated.

Results

The mean age was 52.6 ± 4.9 and 52.2 ± 5.0 years in the HRT and Control Groups, respectively. Whereas there was no change in the Controls, the weight, waist/hip ratio, and BMI increased and diastolic blood pressure decreased in the HRT patients. LDL-c, VLDL-c and lipoprotein (a) levels were significantly higher in the HRT Group in the sixth month; however, total cholesterol and LDL-c increased in the Controls but VLDL-c and lipoprotein (a) did not. CRP and homocysteine significantly increased and fibrinogen decreased, whereas in the Control Group no significant change was detected. A significant improvement in HbA1c and OGTT was found in both the groups, whereas a significant reduction was measured only in the HRT Group.

Conclusions

In response to 6 months of HRT, there was an increase in weight, BMI, and waist/hip ratio as known cardiovascular risk factors, but no significant impact on lipid profile and glucose metabolism could have been clearly demonstrated. A mixed effect profile of HRT on the state of inflammation (increase in CRP and homocysteine, decrease in fibrinogen) was observed.

Stramba-Badiale M (2009) Postmenopausal hormone therapy and the risk of cardiovascular disease. J Cardiovasc Med (Hagerstown) 10(4):303–309

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMed

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605–613CrossRefPubMed

Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, HERS Research Group (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49–57CrossRefPubMed

Zegura B, Keber I, Sebestjen M, Koenig W (2003) Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 168:123–129CrossRefPubMed

Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237–242PubMed

Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843CrossRefPubMed

Christodoulakos GE, Panoulis CPC, Lambrinoudaki IV, Dendrinos SG, Rizos DA, Creatsas GC (2004) Effect of hormone replacement therapy and tibolone on serum total homocysteine levels in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 112:74–77CrossRefPubMed

Li C, Samsioe G, Borgfeldt C, Bendahl PO, Wilawan K, Aberg A (2003) Low-dose hormone therapy and carbohydrate metabolism. Fertil Steril 79:550–555CrossRefPubMed

10.

Friedewald WT, Levy RI, Friedrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifugate. Clin Chem 18:499–502PubMed

11.

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Writing Group for the PEPI Trial. JAMA 273:199–208

12.

Cooper BC, Burger NZ, Toth MJ, Cushman M, Sites CK (2007) Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposity. Am J Obstet Gynecol 196(2):123–127CrossRefPubMed

13.

Kimmerle R, Heinemann L, Heise T, Bender R, Weyer C, Hirschberger S, Berger M (1999) Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 6:36–42CrossRefPubMed

14.

Vehkavaara S, Westerbacka J, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Yki-Jarvinen H (2000) Effect of estrogen replacement therapy on insulin sensitivity of glucose metabolism and preresistance and resistance vessel function in healthy postmenopausal women. J Clin Endocrinol Metab 85:4663–4670CrossRefPubMed

15.

Villa P, Sagnella F, Perri C, Suriano R, Costantini B, Macri F, Ricciardi L, Lanzone A (2008) Low and standard-estrogen dosage in oral therapy: dose dependent effects on insulin and lipid metabolism in healthy postmenopausal women. Climacteric 11:498–508CrossRefPubMed

16.

The Expert Committee on the diagnosis and classification of diabetes mellitus (2003) Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26:3160–3167

17.

Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, Clarkson TB, Mendelsohn M, Lobo RA, Judelson DR, Nachtigall LE, Heward CB, Hecht H, Jaff MR, Harman SM, Women’s Health Initiative (2004) The Women’s Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 81:1498–1501CrossRefPubMed

18.

Sare GM, Gray LJ, Bath PM (2008) Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 29:2031–2041CrossRefPubMed

19.

Farag NH, Barshop BA, Mills PJ (2003) Effects of estrogen and psychological stress on plasma homocysteine levels. Fertil Steril 79:256–260CrossRefPubMed

20.

Bayrak A, Aldemir DA, Bayrak T, Corakci A, Dursun P (2006) The effects of hormone replacement therapy on the levels of serum lipids, apoprotein A1, apoprotein B and lipoprotein (a) in Turkish postmenopausal women. Arch Gynecol Obstet 274:289–296CrossRefPubMed

21.

Godsland IF (2001) Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 75:898–915CrossRefPubMed

22.

Perry W, Wiseman RA (2002) Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women: effect on lipids, coagulation factors, hematology and biochemistry. Maturitas 42:157–164CrossRefPubMed

23.

Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP (2002) A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 77:945–951CrossRefPubMed

24.

Kernohan AF, Sattar N, Hilditch T, Cleland SJ, Small M, Lumsden MA, Connell JM, Petrie JR (2007) Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. Clin Endocrinol 66(1):27–34

25.

Gram J, Bladbjerg EM, Moller L, Sjol A, Jespersen J (2000) Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study. J Intern Med 247:205–212CrossRefPubMed

26.

Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733PubMed

27.

Ylikorkala O, Evio S, Valimaki M, Tiitinen A (2003) Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women. Fertil Steril 80:541–545CrossRefPubMed

28.

Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH (1999) Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 281:1817–1821CrossRefPubMed

29.

Evio S, Tiitinen A, Turpeinen U, Ylikorkala O (2000) Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertil Steril 74:1080–1083CrossRefPubMed

30.

Bruschi F, Pino DD, Fiore V, Parazzini F, Di Pace R, Cesane BM, Melotti D, Crosignani PG (2004) Effect of oral or transdermal hormone replacement therapy on homocysteine levels; a randomized clinical trial. Maturitas 48:33–38CrossRefPubMed

31.

Yilmazer M, Fenkci V, Fenkci S, Sonmezer M, Aktepe O, Altindis M, Kurtay G (2003) Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. Maturitas 46:245–253CrossRefPubMed

32.

Norris LA, Joyce M, O’Keeffe N, Sheppard BL, Bonnar J (2002) Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas 43:125–133CrossRefPubMed

Titel: Effects of hormone replacement therapy on glucose and lipid profiles and on cardiovascular risk parameters in postmenopausal women
verfasst von: Banu Bingol
Ziya Gunenc
Murat Yilmaz
Aydan Biri
Bülent Tiras
Haldun Güner
Publikationsdatum: 01.05.2010
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 5/2010
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-009-1169-y

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Effects of hormone replacement therapy on glucose and lipid profiles and on cardiovascular risk parameters in postmenopausal women

Abstract

Objectives

Methods

Results

Conclusions

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Update Gynäkologie

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Computed tomographic angiography in diagnosis and management of placental polyp with neovascularization

Pregnancy outcome of patients with dermoid and other benign ovarian cysts

A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study

3D color Doppler of monoamniotic twin cord entanglement

Polycystic ovaries: review of medical information on the internet for patients

Cotyledonoid leiomyoma and non-descent vaginal hysterectomy

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Update Gynäkologie